Skip to main content
  • Saved

from Pathologist Connect made a Post

a group of researchers from Memorial Sloan Kettering Cancer Center reported in the journal Science Translational Medicine that a specific pattern, or “signature,” of markers on immune cells in the blood is a likely biomarker of response to checkpoint immunotherapy. Within this immune signature, a molecule LAG-3 provided key information identifying patients with poorer outcomes.

MSK Study Identifies Biomarker That May Help Predict Benefits of Immunotherapy

MSK Study Identifies Biomarker That May Help Predict Benefits of Immunotherapy

Source :

https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy

In recent years, immune-based treatments for cancer have buoyed the hopes of doctors and patients alike. Drugs called immune checkpoint inhibitors have provided lifesaving benefits to a growing list of people with several types of cancer, including melanoma, lung cancer, bladder cancer, and many more.